[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568538":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":21,"centralContacts":25,"locations":32,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Soonchunhyang University Hospital","OTHER",[8,12,15,18],{"label":9,"type":10,"description":11,"interventionNames":10},"PPI-BID group",null,"Standard dose of PPI bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid 14 days",{"label":13,"type":10,"description":14,"interventionNames":10},"Tegoprazan-BID group","Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days",{"label":16,"type":10,"description":17,"interventionNames":10},"PPI-QID group","Standard dose of PPI bid, amoxicillin 500 mg qid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid 14 days",{"label":19,"type":10,"description":20,"interventionNames":10},"Tegoprazan-QID group","Tegoprazan 50 mg bid, amoxicillin 500 mg qid, clarithromycin 500 mg bid,tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days",[22],{"name":23,"affiliation":5,"role":24},"Jun-Hyung Cho, M.D.","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Jun-Hyung Cho","CONTACT","+82-2-709-9202","9581","chojhmd@naver.com",[33],{"facility":34,"status":35,"city":36,"state":10,"zip":37,"country":38,"countryCode":10,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Digestive Disease Center, Soonchunhyang University Hospital","RECRUITING","Seoul","04401","South Korea",{"type":40,"coordinates":41},"Point",[42,43],126.9784,37.566,{"lat":43,"lon":42},[46],{"name":23,"role":28,"phone":29,"phoneExt":10,"email":31},{"type":24,"investigatorFullName":27,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Professor","100568538","tegoprazan--versus-ppi-based-h-pylori-eradication-100568538",false,"NCT06682533","Tegoprazan- Versus PPI-based H. Pylori Eradication","Efficacy and Tolerability of 14-Day Tegoprazan-based Triple Therapy for Eradication of Helicobacter Pylori Eradication: A Retrospective Study","Inclusion Criteria:\n\n* Gastroscopy can be performed\n* H. pylori test and pathological analysis can be performed\n\nExclusion Criteria:\n\n* Age \\\u003C 20 or \\> 80 years\n* Anemia (serum hemoglobin level \\\u003C 10 g\u002FdL)\n* Severe systemic disease\n* Advanced chronic liver disease\n* Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics\n* History of H. pylori eradication\n* Drug allergy to antibiotics\n* History of gastric surgery\n* Recent history of upper gastrointestinal bleeding","ALL","20 Years","80 Years",{"count":60,"type":61},200,"ESTIMATED","1 Year","OBSERVATIONAL","In 2015, vonoprazan, a potassium-competitive blocker (P-CAB), was launched in Japan and used as an alternative for proton pump inhibitors (PPIs) for eradicating Helicobacter pylori. In recent studies, vonoprazan-based triple therapy significantly increased the eradication rate from 72.8% to 87.9%, compared to PPI treatment group. Accordingly, the Japanese Helicobacter treatment guidelines recommend prescribing P-CAB for eradication treatment. In 2018, a new P-CAB, tegoprazan, was developed in Korea and approved for gastric ulcer treatment. Subsequently, it was proven effective in the treatment of reflux esophagitis compared to PPIs in a non-inferiority clinical trial. P-CAB can increase the gastric pH to 6 or higher within 7 hours after taking tegoprazan. Because tegoprazan can be taken after meals, it can improve patient compliance for H. pylori eradication. Unlike vonoprazan in Japan, however, tegoprazan-based eradication in Korean population was similar to conventional PPI-based treatment. To date, the eradication success rates of PPI and tegoprazan-based triple therapy were 76.4-84.2% and 77.3-84.3%, respectively, and there was no significant difference between the two treatment groups.\n\nBismuth has long been used as a semi-metal in the dyspepsia and traveler's diarrhea. In H. pylori eradication therapy, several guidelines recommended the addition of bismuth to treatment regimens. Recently, bismuth was added to the 2-week triple regimen to increase the first-line H. pylori eradication rate in countries with high antibiotic resistance. The H. pylori eradication significantly increased from 87.5-88.1% to 95.8-97.3% in a recent study. The odds ratio was 1.63-2.18 in bismuth-added treatment group, compared to no use of bismuth group. In subgroup analysis, odd ratio was 1.66-2.22 in high clarithromycin-resistant areas. However, there was no comparative analysis of PPIs and tegoprazan in a bismuth-added triple therapy.",[66],"H.Pylori Infection","2026-04-21",{"date":69,"type":70},"2026-04-23","ACTUAL",{"date":72,"type":70},"2024-12-01",{"date":74,"type":61},"2026-12-31",{"name":5,"class":6},1]